News|Articles|August 24, 2023

FDA Warns Public to Not Purchase or Use Specific Eye Drop Brands

The federal agency says everyone should immediately stop using Dr. Berne’s MSM Drops 5% Solution and LightEyez MSM Eye Drops–Eye Repair due to bacterial contamination, fungal contamination, or both.

The FDA announced a warning this week to consumers about 2 specific eye drop brands for fears of contamination that could cause series eye conditions. The 2 brands in question are: Dr Berne’s MSM Drops 5% Solution and LightEyez MSM Eye Drops.

In the announcement, the FDA wrote it was not aware of any adverse event reports associated with use of either products at that time (August 22). Patients who have signs or symptoms of an eye infection should talk to their health care professional or otherwise seek medical care immediately.

Listed in the table below are the contaminants found in the eye drops:



Dr Berne verbally agreed on August 21, to voluntary recall the Dr. Berne’s MSM Drops 5% Solution. The FDA emailed LightEyez Limited on August 21 to seek to discuss FDA’s concerns with LightEyez products distributed in the US and further steps to protect consumers from using the contaminated eye drops. To date, LightEyez has not responded to FDA or taken action to protect consumers.

When using contaminated eye drops, it can result in minor to serious vision-threatening infection which could possibly progress to a life-threatening infection.

The FDA provided information on how to report adverse events or quality problems with any medicine to FDA’s MedWatch Adverse Event Reporting program:

  • Complete and submit the report online at Medwatch; or
  • Download and complete the form, then submit it via fax at 1-800-FDA-0178.

The federal agency encourages both the general public and providers to report such issues.


Related to this article

IDSA/ESCMID Statement on Staphylococcus aureus: Follow-Up Blood Cultures
Staphylococcus aureus Bacteremia (SAB) causes significant morbidity and globally is the leading cause of death from bloodstream infection. This month, the IDSA and ESCMID released 7 consensus statements to assist in managing individuals with SAB. This review will focus on the adult patient population and additional information on pediatric population statements can be assessed in the guideline. Here is a closer look at Consensus Statement 2: Follow-up Blood Cultures.
Measles Update: September 25, 2026
The latest CDC numbers show a 5.4% increase of measles cases from week-to-week. This year has already become the worst for the number of measles cases in the US since the disease was declared eliminated in 2000. With the start of respiratory virus season, case numbers are expected to continue to increase significantly.
Asymptomatic C difficile Colonization in Infants Doesn’t Mean Benign
A new study in infants challenges the long-standing belief about the pathogen’s effects in the youngest pediatric population. Senior author Joseph Zackular, PhD, provides insights around his work including how it reshapes gut development and offers potential intervention strategies to shield neonates.